Trials / Completed
CompletedNCT00680017
30 Week Study of the Combination of ABT-335 and Rosuvastatin Compared to Rosuvastatin Monotherapy for Subjects With Dyslipidemia and Stage 3 Chronic Kidney Disease
A 30-Week, Multicenter, Randomized, Double-Blind, Parallel-Group Study of the Combination of ABT-335 and Rosuvastatin Compared to Rosuvastatin Monotherapy in Dyslipidemic Subjects With Stage 3 Chronic Kidney Disease
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 280 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to evaluate the safety and efficacy of the combination of ABT-335 plus rosuvastatin in dyslipidemic subjects with Chronic Kidney Disease (CKD) Stage 3.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ABT-335 plus rosuvastatin | ABT-335 45 mg plus rosuvastatin 5 mg for 8 weeks, then ABT-335 45 mg plus rosuvastatin 10 mg for 8 weeks |
| DRUG | Rosuvastatin | Rosuvastatin 5 mg for 8 weeks then rosuvastatin 10 mg for 8 weeks |
Timeline
- Start date
- 2008-06-01
- Primary completion
- 2011-04-01
- Completion
- 2011-04-01
- First posted
- 2008-05-19
- Last updated
- 2012-10-03
- Results posted
- 2012-07-16
Locations
114 sites across 2 countries: United States, Puerto Rico
Source: ClinicalTrials.gov record NCT00680017. Inclusion in this directory is not an endorsement.